BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Iambic Therapeutics\, Inc readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Iambic Therapeutics\, Inc's drugs
  run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06253871-2528@assetmemo.bio
DTSTAMP:20261121T005929Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:IAM1363: Phase 1/2 readout est. (NCT06253871)
DESCRIPTION:IAM1363\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A Pha
 se 1/2 Study of IAM1363 in HER2 Cancers\nEstimated primary completion: Oct
 ober 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/iam1363#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT062538
 71
URL:https://assetmemo.bio/drug/iam1363#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
